Tags

Type your tag names separated by a space and hit enter

[Paliperidone, risperidone].
Nihon Rinsho. 2013 Apr; 71(4):654-9.NR

Abstract

Risperidone, a serotonin-dopamine antagonist, is effective in preventing delusions and hallucinations by D2 receptor antagonism and treating negative symptoms by 5-HT2A receptor antagonism. It is less likely to produce extrapyramidal symptoms than conventional antipsychotics, enabling safe drug therapy for schizophrenia. Paliperidone, based on 9OH-risperidone(major metabolite of risperidone), was developed to make the best use of the high therapeutic efficacy of Risperdal and enable continued treatment with lower prevalence of adverse events. Its mechanism of action as an extended-release tablet ensures slow release of the active ingredient, contributing to the lower prevalence of adverse events. With these pharmacological characteristics in mind, the two drugs can serve as safe and effective drug therapy.

Authors+Show Affiliations

Department of Neuropsychiatry, Iwate Medical University.No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

23678595

Citation

Takeuchi, Katsuya, et al. "[Paliperidone, Risperidone]." Nihon Rinsho. Japanese Journal of Clinical Medicine, vol. 71, no. 4, 2013, pp. 654-9.
Takeuchi K, Sanjo K, Sakai A. [Paliperidone, risperidone]. Nihon Rinsho. 2013;71(4):654-9.
Takeuchi, K., Sanjo, K., & Sakai, A. (2013). [Paliperidone, risperidone]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 71(4), 654-9.
Takeuchi K, Sanjo K, Sakai A. [Paliperidone, Risperidone]. Nihon Rinsho. 2013;71(4):654-9. PubMed PMID: 23678595.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Paliperidone, risperidone]. AU - Takeuchi,Katsuya, AU - Sanjo,Katsumi, AU - Sakai,Akio, PY - 2013/5/18/entrez PY - 2013/5/18/pubmed PY - 2013/9/26/medline SP - 654 EP - 9 JF - Nihon rinsho. Japanese journal of clinical medicine JO - Nihon Rinsho VL - 71 IS - 4 N2 - Risperidone, a serotonin-dopamine antagonist, is effective in preventing delusions and hallucinations by D2 receptor antagonism and treating negative symptoms by 5-HT2A receptor antagonism. It is less likely to produce extrapyramidal symptoms than conventional antipsychotics, enabling safe drug therapy for schizophrenia. Paliperidone, based on 9OH-risperidone(major metabolite of risperidone), was developed to make the best use of the high therapeutic efficacy of Risperdal and enable continued treatment with lower prevalence of adverse events. Its mechanism of action as an extended-release tablet ensures slow release of the active ingredient, contributing to the lower prevalence of adverse events. With these pharmacological characteristics in mind, the two drugs can serve as safe and effective drug therapy. SN - 0047-1852 UR - https://www.unboundmedicine.com/medline/citation/23678595/[Paliperidone_risperidone]_ L2 - https://medlineplus.gov/schizophrenia.html DB - PRIME DP - Unbound Medicine ER -